SBC SBC Medical Group (SBC) Insider Trading, Ownership & Congress Trades
Healthcare Services · Services-offices & clinics of doctors of medicine · CIK 0001930313
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
0
13F, latest reported quarter
SBC Medical Group insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
No insider purchases or sales are on record for SBC Medical Group Holdings Inc in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Apr 21, 2026.
- The trade is 0.6% of the 78,839,460 shares held after it.
- No other insider sold within 30 days.
Insider activity: Chairman and CEO Aikawa Yoshiyuki sold about $1.4M of SBC on Apr 28, 2026.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Mar 6, 2026.
- The trade is 3.9% of the 79,304,460 shares held after it.
- No other insider sold within 30 days.
Insider activity: Chairman and CEO Aikawa Yoshiyuki sold about $9.4M of SBC on Apr 21, 2026.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 513.3% of the 861,600 shares held after it.
- No other insider sold within 30 days.
Insider activity: Chairman and CEO Aikawa Yoshiyuki sold about $9.4M of SBC on Mar 6, 2026, the largest insider sale at the company on our record.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 0.2% of the 2,920,995 shares held after it.
- No other insider sold within 30 days.
Insider activity: Insider ZUU Funders Co. Ltd. sold about $45.5K of SBC on Sep 19, 2024, the largest insider sale at the company on our record.4 transactions on record · a thin record, read with care
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
under five funds report holding it
Revenue
-15.5% year over year
below 86% of Healthcare Services
Margin
29.4% net margin
more than 97% of Healthcare Services
Buybacks
$5.0M repurchased, FY to 2025-12-31
below 90% of Healthcare Services
Short interest
4.5% of the float short (float per yahoo 2026-10-26) · 3.4 days to cover · settled 2026-09-30
below 73% of Healthcare Services
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch SBC
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+37.3%12M
Insider sell
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns SBC: institutional holders (13F)
13F holdings, latest reported quarter
SEC 13F
No reported 13F holders
No fund above the reporting threshold listed this stock last quarter. That is a fact, not missing data.
Congress trades in SBC
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
SBC planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
Each figure here is a federal filing, dated the day it went public, so you can test what was knowable then.
SBC financials
Revenue growth
-15.5%
XBRL, annual
Net margin
29.4%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$175.2M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM SBC
| FY Dec 2025 | $173.6M |
| FY Dec 2024 | $205.4M |
| FY Dec 2023 | n/a |
| Jun 2026 | $49.2M |
| Mar 2026 | $43.1M |
| Dec 2025 | $39.6M |
| Sep 2025 | $43.4M |
| Jun 2025 | $43.4M |
| Mar 2025 | $47.3M |
| Dec 2024 | $44.4M |
| Sep 2024 | $53.1M |
At each fiscal year end
Single quarter
Net margin, TTM
+28.0%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM SBC
| FY Dec 2025 | +29.4% |
| FY Dec 2024 | +22.7% |
| FY Dec 2023 | n/a |
| Jun 2026 | +21.7% |
| Mar 2026 | +26.3% |
| Dec 2025 | +35.9% |
| Sep 2025 | +29.6% |
| Jun 2025 | +5.7% |
| Mar 2025 | +45.4% |
| Dec 2024 | +14.7% |
| Sep 2024 | +5.3% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$61.8M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM SBC
| FY Dec 2025 | $23.3M |
| FY Dec 2024 | $18.0M |
| FY Dec 2023 | n/a |
| Jun 2026 | $22.4M |
| Mar 2026 | $9.1M |
| Dec 2025 | $51.2M |
| Sep 2025 | -$20.9M |
| Jun 2025 | -$8.6M |
| Mar 2025 | $1.7M |
| Dec 2024 | -$7.9M |
| Sep 2024 | $4.6M |
At each fiscal year end
Single quarter
Debt to equity
0.14x
long-term 2026-06-30 plus current 2026-06-30; equity 2026-06-30
Debt to equity SBC
| FY Dec 2025 | 0.17x |
| FY Dec 2024 | 0.04x |
| FY Dec 2023 | 0.00x |
| Jun 2026 | 0.14x |
| Mar 2026 | 0.16x |
| Dec 2025 | 0.17x |
| Sep 2025 | 0.09x |
| Jun 2025 | 0.03x |
| Mar 2025 | 0.03x |
| Dec 2024 | 0.04x |
| Sep 2024 | 0.02x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
1.65x
TTM operating cash flow over long-term 2026-06-30 plus current 2026-06-30
Cash flow to debt SBC
| FY Dec 2025 | 0.57x |
| FY Dec 2024 | 3.00x |
| FY Dec 2023 | 153.94x |
| Jun 2026 | 1.65x |
| Mar 2026 | 0.79x |
| Dec 2025 | 0.57x |
| Sep 2025 | -1.62x |
| Jun 2025 | -1.18x |
| Mar 2025 | 2.64x |
| Dec 2024 | 3.00x |
| Sep 2024 | 15.84x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+19.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity SBC
| FY Dec 2025 | +23.0% |
| FY Dec 2024 | +27.6% |
| FY Dec 2023 | n/a |
| Jun 2026 | +19.3% |
| Mar 2026 | +16.9% |
| Dec 2025 | +23.0% |
| Sep 2025 | +19.1% |
| Jun 2025 | +26.3% |
| Mar 2025 | +41.9% |
| Dec 2024 | +27.6% |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+13.6%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets SBC
| FY Dec 2025 | +15.8% |
| FY Dec 2024 | +17.8% |
| FY Dec 2023 | n/a |
| Jun 2026 | +13.6% |
| Mar 2026 | +12.1% |
| Dec 2025 | +15.8% |
| Sep 2025 | +14.0% |
| Jun 2025 | +19.9% |
| Mar 2025 | +32.4% |
| Dec 2024 | +17.8% |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
+35.2%
operating income after a 33.5% effective tax rate, over long-term 2026-06-30 plus current 2026-06-30 plus average of 2025-06-30 and 2026-06-30 minus cash
Return on invested capital SBC
| FY Dec 2025 | +34.9% |
| FY Dec 2024 | +72.7% |
| FY Dec 2023 | n/a |
| Jun 2026 | +35.2% |
| Mar 2026 | +27.2% |
| Dec 2025 | +34.9% |
| Sep 2025 | +32.0% |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | +72.7% |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
+22.4%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed SBC
| FY Dec 2025 | +25.7% |
| FY Dec 2024 | +37.9% |
| FY Dec 2023 | n/a |
| Jun 2026 | +22.4% |
| Mar 2026 | +21.7% |
| Dec 2025 | +25.7% |
| Sep 2025 | +23.7% |
| Jun 2025 | +42.5% |
| Mar 2025 | +55.7% |
| Dec 2024 | +37.9% |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
11.43x
close 2026-10-26 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
P/E, trailing SBC
| FY Dec 2025 | 8.80x |
| FY Dec 2024 | 11.35x |
| FY Dec 2023 | n/a |
| Jun 2026 | 6.55x |
| Mar 2026 | 10.72x |
| Dec 2025 | 8.80x |
| Sep 2025 | 10.59x |
| Jun 2025 | 14.50x |
| Mar 2025 | 6.38x |
| Dec 2024 | 11.35x |
| Sep 2024 | 13.74x |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$405.9M
market value at close 2026-10-26 on 2026-07-31 shares, plus long-term 2026-06-30 plus current 2026-06-30, minus cash 2026-06-30
Enterprise value SBC
| FY Dec 2025 | $321.4M |
| FY Dec 2024 | $454.6M |
| FY Dec 2023 | n/a |
| Jun 2026 | $170.4M |
| Mar 2026 | $302.1M |
| Dec 2025 | $321.4M |
| Sep 2025 | $344.8M |
| Jun 2025 | $335.4M |
| Mar 2025 | $205.6M |
| Dec 2024 | $454.6M |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+11.2%
TTM free cash flow over market value at close 2026-10-26
FCF yield SBC
| FY Dec 2025 | +5.3% |
| FY Dec 2024 | +3.1% |
| FY Dec 2023 | n/a |
| Jun 2026 | +19.5% |
| Mar 2026 | +7.2% |
| Dec 2025 | +5.3% |
| Sep 2025 | -7.9% |
| Jun 2025 | -2.1% |
| Mar 2025 | +5.1% |
| Dec 2024 | +3.1% |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
0.24x
P/E over trailing EPS growth of 47%: four quarters to 2026-06-30 against the four to 2025-06-30
PEG, trailing SBC
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| Jun 2026 | 0.14x |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $173.6M | $205.4M | $193.5M | n/a |
| Gross profit | $127.3M | $156.1M | $137.3M | n/a |
| Operating income | $67.5M | $70.3M | $70.7M | n/a |
| Net income | $51.0M | $46.6M | $39.4M | n/a |
| EPS (diluted) | 0.50 | 0.48 | 0.42 | n/a |
| Operating cash flow | $24.7M | $20.6M | $50.7M | n/a |
| Cash | $163.8M | $125.0M | $103.0M | $485.6K |
| Long-term debt | $42.8M | $6.6M | n/a | n/a |
| Buybacks | $5.0M | $0 | n/a | n/a |
SEC XBRL, fiscal years, as known on 2026-10-28
SBC Stock Sonar score 4/7 axes
Find similar shapesCompareSBC ranks highest on profitability (90th percentile) and financial health (76th), and lowest on growth (14th), among Healthcare Services peers.
4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
